Special Issue

Biomarkers for Cancer Immunity

Message from the Guest Editor

Cancer immunotherapy, such as immune checkpoint inhibitors and CAR-T cells, has revolutionized cancer treatment, but the outcomes differ widely, with only a few patients achieving lasting benefits. This inconsistency is due to the complexity and heterogeneity of the tumor microenvironment (TME). which current therapies targeting classical pathways like CTLA-4 and PD-1/PD-L1 and limited immune cell populations struggle to address. To address this issue, there is a need to identify novel biomarkers, better understand diverse immune cell populations, and develop combinatory strategies. These efforts will help overcome resistance mechanisms and improve outcomes in cancer immunotherapy. This Special Issue aims to inspire new insights into cancer immunity mechanisms, novel biomarkers, and effective combinational strategies for cancer immunotherapies. We welcome submissions of original research, review articles, mini-reviews, and perspectives that explore the fundamental mechanisms of cancer immunotherapy and the therapeutic potential of novel combination strategies.

Guest Editor

Dr. Xuyao Zhang

Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai 201203, China

Deadline for manuscript submissions

31 August 2025



Biology

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.4 Indexed in PubMed



mdpi.com/si/214287

Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biology@mdpi.com

mdpi.com/journal/ biology





Biology

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.4 Indexed in PubMed





Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editors-in-Chief

Prof. Dr. Jukka Finne

Research Programme in Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya

Integrative Systems Biology Institute, University of Valencia and CSIC, 46980 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (General Agricultural and Biological Sciences)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

